1366p * risk-benefit index of tamoxifen and raloxifene for chemoprevention of korean breast cancer

Conclusions: Women under the age 40 had more benefit than risk from tamoxifen chemoprevention. In the postmenopausal women with a uterus, raloxifene has more favorable risk-benefit index than tamoxifen.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Authors: Tags: prevention and screening Source Type: research